Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 29, 2026Journal of Clinical Oncology

Iberdomide (Iber) maintenance following upfront autologous stem cell transplant (ASCT) in multiple myeloma (MM).

View Full Paper
Ask AI
Bookmark
Share

Authors

TWTanya M. WildesVSVera J. SumanJHJ Hillengass

Discussion

Loading...

Member takes

Overview

Randomized trial evaluates Iberdomide's effectiveness as maintenance therapy in multiple myeloma, suggesting potential for improved management.

Key Points

  • To evaluate the efficacy and safety of Iberdomide maintenance following autologous stem cell transplant in multiple myeloma patients.
  • Phase II trial with patients aged ≥19 with multiple myeloma and partial response post-ASCT
  • Iberdomide administered at 1 mg daily for 21 days in a 28-day cycle until disease progression or toxicity
  • Minimal residual disease assessed at various intervals during treatment.
  • 29% of patients discontinued Iberdomide within 1 year due to adverse events, predominantly neutropenia
  • 85% MRD-negative rate post-cycle 12, and 100% post-cycle 24
  • Promising activity indicated by high rates of progression-free patients at 1 year with a majority achieving complete response.

Cite This Study

Wildes et al. (2026) studied this question.

synapsesocial.com/papers/6a192e68fab5b468c44176d0https://doi.org/10.1200/jco.2026.44.16_suppl.7528
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Iberdomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: An update from the phase 2 EMN26 trial2025 · 3 citations
  2. 2Efficacy and safety of iberdomide, daratumumab, bortezomib, and dexamethasone in patients with newly diagnosed multiple myeloma.2026
  3. 3Iberdomide plus daratumumab and dexamethasone (IberDd) in patients with newly diagnosed multiple myeloma by renal function: A subgroup analysis of the CC-220-MM-001 trial2025
  4. 4Longitudinal analysis of MRD negativity and immune dynamics in patients with transplant-ineligible newly diagnosed multiple myeloma treated with iberdomide, daratumumab, and dexamethasone from the CC-220-MM-001 trial2025
  5. 5Multidimensional Single Cell Analysis Shows Increased T/NK Cell Subsets in Both Blood and Bone Marrow of Iberdomide (CC-220) Treated Relapsed/Refractory Multiple Myeloma Patients2019 · 11 citations